radretumab
mAbexperimentalADC
Radretumab is an antineoplastic. Philogen, a pharmaceutical company specializing in antibody-drug conjugates, is developing it as a conjugate of Iodine-131 to an antibody which binds to fibronectin extra domain-B for treatment of Hodgkin lymphoma. — Wikipedia
Clinical trial activity
3 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Nov 1, 2008 (NCT01242943)
Timeline
Indications
Mechanism of action
- FibronectinANTAGONIST
FN1 antagonist
- FibronectinBINDING AGENT
Fibronectin binding agent
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
- Payload
- 131-iodine
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaRadretumab ↗
- ChEMBLCHEMBL1743060 ↗
Also known as
- 131i-l19sip
- radretumab
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01124812 | Phase 1 | May 31, 2010 | Philogen S.p.A. |
| NCT01125085 | Phase 2 | Oct 1, 2009 | Fondazione Giovanni Pascale, Philogen S.p.A., University of London |
| NCT01242943 | Phase 1/Phase 2 (Phase 2) | Nov 1, 2008 | Philogen S.p.A., University of London, University of Pisa |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Philogen S.p.A. | For profit | 3 | 3 | 2 | 2008 |
| University of London | Academic/Hospital | 2 | 0 | 1 | 2008 |
| Fondazione Giovanni Pascale | Academic/Hospital | 1 | 0 | 1 | 2009 |
| University of Pisa | Academic/Hospital | 1 | 0 | 1 | 2008 |
4 organizations
Page 1 / 1